Abelson interactor 1 splice isoform-L plays an anti-oncogenic role in colorectal carcinoma through interactions with WAVE2 and full-length Abelson interactor 1

Figure 1 Diagram of Abelson interactor 1 isoforms and polymerase chain reaction primers used to measure expression levels of Abelson interactor 1. A: Schematic comparison of the exons and functional domains of two major isoforms of Abelson interactor 1 (ABL1): ABL1 splice isoform L (ABI1-SiL) and ABL1 splice isoform A (ABI1-p65). ABI1-SiL has conserved WAVE2-binding and SH3 domains, but lacks the homeo-domain homologous region and the majority of the PxxP- and Pro-rich domain; B: Schematic showing locations of ABI1 universal 1 (ABI1-U1)-, ABI1 universal 2 (ABI1-U2)-, and ABI1-SiL-specific primers. Primers were selected to target exon 3, as it represents a major structural difference between ABI1-SiL and other ABI1 variants. Three sets of primers were designed to analyze the expression of ABI1-SiL in colorectal carcinoma cells and tissues. Transcript variant 12-specific primers were used for qualitative analysis, while transcript variant 1-12 universal (ABI1-U1) and transcript variant 1-11 universal (ABI1-U2) primers were used for quantitative analysis of ABI1-SiL expression. ABI1: Abelson interactor 1; HHR: Homeo-domain homologous region.